NAMENDA® (memantine hydrochloride) should not be taken by anyone
who is allergic (hypersensitive) to memantine, the active substance in NAMENDA,
or who has had a bad reaction to NAMENDA or any of its ingredients. Before starting
NAMENDA, talk to the healthcare provider about all of the patient's past and present
medical conditions, including seizure disorders, difficulty passing urine, liver,
kidney or bladder problems. If the patient is taking other medications (including
those without a prescription), ask the healthcare provider if NAMENDA is right for
the patient.

NAMENDA® (memantine hydrochloride) is indicated for the treatment
of moderate to severe dementia of the Alzheimer's type. NAMENDA is available by
prescription only.

Taking NAMENDA

Important message regarding NAMENDA® (memantine HCl). Forest Laboratories,
LLC, a wholly owned subsidiary of Actavis plc, plans to continue the sale of NAMENDA (memantine
HCl) tablets in accordance with a court order, which we are appealing.
Additionally, the oral solution of NAMENDA and once-daily NAMENDA XR®
(memantine HCl) extended-release capsules remain available. Previously we had announced that
we planned to discontinue the sale of NAMENDA tablets.

How will my loved one take NAMENDA?

If you think NAMENDA (memantine HCl) may be right for your loved one, talk to your
doctor about how to begin therapy.

Taking NAMENDA:

NAMENDA is recommended to be taken twice daily

NAMENDA can be taken with or without food

NAMENDA is available in tablet and liquid form

Therapy begins at a low dose (5 mg per day) of NAMENDA and is gradually increased
until the recommended target dose (10 mg, twice daily) is reached. A recommended
dosing schedule for beginning NAMENDA therapy is provided below.

Recommended NAMENDA dosing schedule:

Week 1: Starting on Day 1. Take one 5 mg tablet in the morning,
each day.

Week 2: Starting on Day 8. Take one 5 mg tablet in the morning
and one 5 mg tablet at night, each day.

Week 3: Starting on Day 15. Take one 10 mg tablet in the morning
and one 5 mg tablet at night, each day.

Week 4: Starting on Day 22. Take one 10 mg tablet in the morning
and one 10 mg tablet at night, each day.

A dosing pack guides patients through the first four weeks of therapy, while dosage
is gradually increased.

Once the recommended target dose of NAMENDA (10 mg, twice daily) has been reached,
people taking NAMENDA can continue with that daily regimen unless instructed otherwise
by their doctors. (For patients with severe renal impairment, 5 mg twice daily
is the recommended dose.) As with all types of prescription medications, do not
stop taking NAMENDA without first talking to a doctor.

NAMENDA® (memantine hydrochloride) is indicated for the treatment of moderate to severe dementia
of the Alzheimer's type. NAMENDA is available by prescription only.

There is no evidence that NAMENDA prevents or slows the underlying disease process in patients with Alzheimer's disease.

IMPORTANT RISK INFORMATION FOR NAMENDA

Who should NOT take NAMENDA?
NAMENDA should not be taken by anyone who is allergic (hypersensitive) to memantine, the active substance in
NAMENDA, or who has had a bad reaction to NAMENDA or any of its ingredients.

What should be discussed with the healthcare provider before taking NAMENDA?
Before starting NAMENDA, talk to the healthcare provider about all of the patient's past and present
medical conditions, including:

Seizure disorders

Difficulty passing urine

Liver, kidney or bladder problems

If the patient is taking other medications (including those without a prescription), ask the healthcare provider if
NAMENDA is right for the patient.

Certain medications, changes in diet, or medical conditions may affect the amount of NAMENDA in the body and
possibly increase side effects.

What are the possible side effects of NAMENDA?
The most common side effects associated with NAMENDA treatment are dizziness, confusion, headache, and constipation.
This is not a complete list of side effects.

If you have any questions, discuss them with your doctor or healthcare professional. For additional information about NAMENDA, call the Forest Medical Information and Communication Department toll-free at 800-678-1605, ext.66297.

Email this Page

Complete the form below

Complete the form below to share the NAMENDA website with someone. A link to this
page will be included in your message.

All fields are required

Your Name

Please enter a name

Your Email Address

Please enter an email address

Recipient's Name

Please enter a name

Recipient's Email

Please enter an email address

Confirm Recipient's Email Address

Emails do not match

Close×

Important message regarding NAMENDA® (memantine HCl). Forest Laboratories,
LLC, a wholly owned subsidiary of Actavis plc, plans to continue the sale of NAMENDA (memantine
HCl) tablets in accordance with a
court order,
which we are appealing. Additionally, the oral solution of NAMENDA and once-daily
NAMENDA XR® (memantine HCl) extended-release capsules remain available. Previously
we had announced that we planned to discontinue the sale of NAMENDA tablets.

Thank you for visiting

You are now leaving the NAMENDA Web site. Links to other Web sites are provided
as a service to you. Forest Laboratories accepts no responsibility for the content
of other Web sites. Would you like to continue?